# US 2020/0138928 A1 · Universal Non-Classical MHC I Vaccines: HLA-E-Restricted Antigenic Peptides as Universal Vaccines to Treat Allergy, Inflammation, Autoimmune and Infectious Diseases, and Cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138928 A1
- Document ID: US20200138928A1
- Status: Published application
- Kind: A1
- Application number: 16/443,710
- Filed: 2019-06-17
- Published: 2020-05-07
- Earliest claimed: 2018-02-26
- Assignees: Swey-Shen Chen
- Inventors: Swey-Shen Chen
- Web page: https://patentgrep.com/patent/US20200138928A1

## CPC

- A61K 39/001114: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/605: {MHC molecules or ligands thereof}
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The embodiment of the invention is to enable universal non-classical MHC I peptide vaccines restricted to HLA-E, HLA-F and HLA-G. An algorithm was develop to predict HLA-E binding immunogenic or suppressorgenic peptides of the autologous origins, e.g., autoantigens, inflammatory antigens, IgE and cancer antigens, and of the microbial origins. Thus, the embodiment of the invention is to load the antigenic peptides of medical and therapeutic importance onto the non-polymorphic HLA-E, HLA-F, and HLA-G culminating in universal vaccines, bypassing highly polymorphic classical MHC I, e.g., HLA-A, HLA-B and HLA-C pathways, in order to treat autoimmune diseases, allergy, inflammatory diseases, cancers, and infectious diseases for all human population. Derlin-1 and UL40 pathways are utilized to enable antigen presentation and vaccine efficacies in the non-classical MHC I pathways.

## Claims

### Claim 1

A composition of the endogenous and exogenous antigenic peptides to HLA-E, -F, -G as universal vaccines, wherein the antigenic peptides are predicted by the Ige predict algorithm or overlapping 8-11-mers, processed and presented by antigen-presenting cells, and wherein the antigenic peptides are derived from auto-antigens, inflammatory molecules, IgE, cancer antigens, allergens, bacterial, fungal and viral antigens.

### Claim 2 (depends on 1)

A claim according to claim 1, wherein the HLA-E-restricted IgE peptides, comprising IgE peptide sequences of SEQ ID: #40 to SEQ ID: #77, are derived from the autologous antigen, IgE (SEQ ID: #78).

### Claim 3 (depends on 1)

A claim according to claim 1, wherein the HLA-E-restricted TNF-a peptides, are derived from the autologous antigen, tumor necrosis factor-1a (SEQ ID: #79, SEQ ID: #80).

### Claim 4

A method of binding the endogenous and exogenous antigenic peptides to HLA-E, -F, -G as universal vaccines, wherein the antigenic peptides processed and presented by antigen-presenting cells are derived from auto-antigens, inflammatory molecules, cancer antigens, allergens, bacterial, fungal and viral antigens, and wherein antigen presenting cells are phenotypically or genetically modified for preferential loading antigenic peptides onto HLA-E, -F, -G, whereby vaccine-activated immune cells provide immune defense or orchestrate immune homeostasis to the vaccinated hosts.

### Claim 5 (depends on 4)

A claim according to claim 4, wherein vaccine-activated immune cells are co-stimulated by positive enhancing second signals, whereby protective CD4+ or CD4/CD8 or CD8+ T cells are elicited for vaccine-mediated immune protection against microbial infection, inflammation and cancers.

### Claim 6 (depends on 4)

A claim according to claim 4, wherein vaccine-activated immune cells are co-stimulated by negative immunoregulatory tolerance-inducing signals, whereby suppressive or immunoregulatory CD4+ or CD4+/CD8+ or CD8+ T cells are elicited for vaccine-mediated immune suppression or homeostasis against inflammation and autoimmune diseases.

### Claim 7 (depends on 4)

A claim according to claim 4, wherein antigen-presenting cells are derived from monocytes, blood dendritic cells, monocyte-derived dendritic cells, tumor biopsies.

### Claim 8 (depends on 4)

A claim according to claim 4, wherein the antigenic peptides are derived from immunoglobulin E, tumor necrosis factor-1.

### Claim 9 (depends on 4)

A claim according to claim 4, wherein antigen-presenting cells are treated with US 11 and US2, or US11, or US6 upon loading of antigenic peptides.

### Claim 10 (depends on 4)

A claim according to claim 4, wherein antigen-presenting cells are treated with siRNA/shRNA of Derlin-1, SEL-1L, HRD1, p97, Ufd1-Npl4, BiP, proteasome inhibitors, heat shock proteins, whereby uploading the antigenic peptides to HLA-E is modulated.

### Claim 11 (depends on 4)

A claim according to claim 4, wherein the routes of vaccination comprise intradermal injections, tattoo gun immunization, and intramuscular injections, electroporation, gene-gun injection, subcutaneous injections, sublingual injections, targeting professional and facultative antigen-presenting cells.

### Claim 12 (depends on 4)

A claim according to claim 4, wherein peptides binding to MHC Ib, e.g., HLA-E, HLA-G, and HLA-F are validated by diminishing the augmented renaturation binding via a canonical indicator peptide to conformation-specific anti-HLA-E solid phase.

### Claim 13 (depends on 4)

A claim according to claim 4, wherein peptides binding to MHC Ib, e.g., HLA-E, HLA-G, and HLA-F are validated by upregulating surface MHC Ib of cell lines defective in TAP ½ such as mutant T2 cells, and cell lines deficient of MHC Ia such as MHC Ib-transfected 0.221 cells.

### Claim 14 (depends on 10)

A claim according to claim 10, wherein the length of the MHC Ib binding peptide is an 8-mer, a 9-mer, a 10-mer and from a 11- to 43-mer.

### Claim 15 (depends on 11)

A claim according to claim 11, wherein the length of the MHC Ib binding peptide is an 8-mer, a 9-mer, a 10-mer and from a 11- to 43-mer.

### Claim 16

A claim of using viral UL40 as a universal vaccine vehicle for inducing peptide and HLA-E, -F, -G-restricted immune immunity or immune tolerance.

### Claim 17 (depends on 16)

A claim according to claim 16, further wherein the natural viral HLA-E leader peptide mimicry is substituted with leader-like peptides of autoimmune antigenic peptides or inflammation-related peptides for inducing immunoregulatory Treg/Ts for a healthy immune homeostasis.

### Claim 18 (depends on 16)

A claim according to claim 16, further wherein the natural viral HLA-E leader peptide mimicry is substituted with leader-like peptides of microbial peptides or cancer antigenic peptides for inducing helper or cytotoxic CD4+, CD8+ or CD4+CD8+ T cells for immune defense against invading microbial pathogens and autochthonous cancers.
